Tanking Biotech Stocks Will Mean a Big 12 months for Deals. Who Could Profit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize firms within the space are finally accepting that share prices aren’t bouncing back anytime soon.

With reality setting in, it’s a buyer’s marketplace for firms searching for acquisitions and partnerships, in keeping with most of the pharmaceutical and medical technology executives who gathered at this yr’s

J.P. Morgan

healthcare investor conference, which wrapped up in San Francisco on Thursday.

Leave a Comment

Copyright © 2024. All Rights Reserved. Finapress | Flytonic Theme by Flytonic.